1. Home
  2. ZSQR vs IKT Comparison

ZSQR vs IKT Comparison

Compare ZSQR & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Z Squared Inc. Common Stock

ZSQR

Z Squared Inc. Common Stock

N/A

Current Price

$3.91

Market Cap

204.6M

Sector

Finance

ML Signal

N/A

Logo Inhibikase Therapeutics Inc.

IKT

Inhibikase Therapeutics Inc.

N/A

Current Price

$1.96

Market Cap

220.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ZSQR
IKT
Founded
2022
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
204.6M
220.5M
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
ZSQR
IKT
Price
$3.91
$1.96
Analyst Decision
Strong Buy
Analyst Count
0
9
Target Price
N/A
★ $6.00
AVG Volume (30 Days)
★ 375.9K
368.1K
Earning Date
08-13-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
50.27
★ 57.76
EPS
N/A
★ N/A
Revenue
★ $1,363,045.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$33.33
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.11
$1.33
52 Week High
$16.62
$2.61

Technical Indicators

Market Signals
Indicator
ZSQR
IKT
Relative Strength Index (RSI) 58.36 34.98
Support Level $2.81 $1.59
Resistance Level $4.64 $2.13
Average True Range (ATR) 0.47 0.10
MACD 0.26 -0.03
Stochastic Oscillator 79.36 22.89

Price Performance

Historical Comparison
ZSQR
IKT

About ZSQR Z Squared Inc. Common Stock

Z Squared Inc is a computing infrastructure company operating computing equipment and expanding into AI infrastructure. The Company's idea is to build on three principles: guide with power by acquiring operating sites where power is already flowing; build for AI workloads by converting that capacity into AI-ready colocation where the customer brings the compute and runs what it needs; and scale with discipline by deploying conversion capital site by site, against signed contracts and operational readiness.

About IKT Inhibikase Therapeutics Inc.

Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.

Share on Social Networks: